我终于看懂经济学人的操作了，
经济学人发这些捧台湾的新闻真的符合专业吗？
如果不符合专业，难道绿共有办法买通他们吗？
其实经济学人就像之前的大纪元新唐人一样，
故意写符合台派觉共口味的新闻，想要赚台派的钱而已。
他们发现台派的钱好赚的话，只会更鄙视台派的智商而已。
※ 引述《goldenfire (喵吞．Freeman)》之铭言：
1.转录网址︰
※ 网址超过一行 请缩网址 ※
经济学人智库报告
https://reurl.cc/MZXG94
杂志新闻：
https://reurl.cc/Xe59pe
2.转录来源︰
※ FB公众人物、FB粉丝团名称、其他来源 ※
经济学人
3.转录内容︰
※ 请完整转载原文 请勿修改内文与编排 ※
媒体完整报导要加入会员，所以就只转贴智库报告了
至于报告的细节也要付费就是
https://imgur.com/SR3isNG
（本图重点：台湾世界最快打完疫苗的国家之一，预计今年底之前）
The rollout of vaccines against the coronavirus (Covid-19) has started in
developed countries, but mass immunisation will take time.
Production represents the main hurdle, as many developed countries have
pre-ordered more doses than they need.
The costs associated with mass immunisation programmes will be significant,
especially for less-developed countries that have limited fiscal resources.
Vaccine diplomacy will play a role in determining which countries get access
to a vaccine in the coming months.
Russia and China will use the rollout of their own coronavirus shots to
advance their interests.
With priority groups vaccinated in rich economies by end-March, The EIU
expects global economic prospects to brighten from mid-2021.
For most middle-income countries, including China and India, the vaccination
timeline will stretch to late 2022.
In poorer economies, widespread vaccination coverage will not be achieved
before 2023, if at all.
In early 2021 three vaccines, from Pfizer (US)-BioNTech (Germany), Moderna
(US) and AstraZeneca-Oxford University (UK), will be rolled out on a massive
scale in developed countries. Meanwhile, Chinese and Russian vaccines are
being rolled out both domestically and to emerging countries such as Egypt,
via diplomatic bilateral deals. This will foster so-called vaccine diplomacy—
with Russia and China trying to bolster their global status via the delivery
of vaccines—this year and beyond.
Countries at the front of the queue—including the UK, the US and most
countries in the EU—are expected to have immunised their priority groups by
end-March, with other wealthy countries catching up by end-June. We therefore
expect that global economic prospects will brighten from mid-2021, with the
global economic rebound gaining speed in the third and fourth quarters.
However, life will not be back to normal by then, as immunisation programmes
for the bulk of the population will continue until mid-2022.
Among middle-income countries, Russia, which has developed its own vaccines,
could be on a similar schedule to richer economies, with mass immunisation
completed by mid-2022. Other middle-income countries, including Mexico and
Brazil, have been promised supplies in return for running clinical trials or
housing production factories. This should give them early access to doses for
priority groups, although their ability to achieve mass vaccination will
depend on other factors including fiscal space, population size, number of
healthcare workers, infrastructure and political will. China and India
represent special cases; both countries have developed their own shots and
are pressing ahead with rollout plans, but the sheer size of their population
means that mass immunisation programmes will stretch until late 2022, in line
with the expected timeline for most middle-income countries.
Finally, some other middle-income countries and most low-income countries
will be relying on COVAX, an initiative led by the WHO that aims to secure
6bn doses of vaccine for poorer countries. The first 2bn of these will be
given in 2021, mainly to healthcare workers (COVAX doses will cover only up
to 20% of the population of each country). However, COVAX supplies may be
slow to arrive, especially if delays in the production for and delivery to
richer countries push back delivery dates for poorer nations. In these
developing countries, widespread vaccination coverage will not be achieved
before 2023, if it happens at all.
Methodology:
This map depicts the latest forecasts from The EIU for the rollout of
coronavirus vaccines, reflecting the time when countries may expect to have
vaccinated the majority (60-70%) of their adult population. Criteria taken
into account include supply deals, production constraints, vaccine hesitancy,
the size of the population, and the availability of healthcare workers. The
data are also adjusted by analysts to reflect specific conditions on the
ground.
“The contrast between rich countries and poorer ones is stark. Most
developing countries will not have widespread access to the shots before 2023
at the earliest. Some of these countries—particularly poorer ones with a
young demographic profile—may well lose the motivation to distribute
vaccines, especially if the disease has spread widely or if the associated
costs prove too high.”
AGATHE DEMARAIS, THE ECONOMIST INTELLIGENCE UNIT GLOBAL FORECASTING DIRECTOR
Ms Demarais adds that “Vaccine diplomacy will also be an important trend to
keep an eye on. Both Russia and China will seek to adopt a transactional
approach to the delivery of vaccines, using coronavirus shots as a bargaining
chip to advance long-standing interests.”
Finally, Ms Demarais adds that “Vaccines against many diseases, such as
polio or tuberculosis, have been available for decades. However, many people
in poorer countries remain unable to get access to them. What was termed a “
novel coronavirus” only one year ago will be with us for the long term,
alongside the many other diseases that have shaped life over the centuries.”
Download our report “Coronavirus vaccines: expect delays” to find out more.
4.附注、心得、想法︰
※ 40字心得、备注 ※
简单来说，经济学人预估何时可以打完的方式是利用
买不买得到疫苗、硬件设备好不好、总人口数、医疗体系完备程度
作为评分要点
所以根据经济学人的预测，台湾会在世界第一批打完疫苗的国家之内
预计在2021年底前会打到群体免疫
甚至比日本、韩国还要快打到60-70%
再贴一次图：
https://imgur.com/SR3isNG
以下开放柯韩五毛崩溃经济学人绿共侧翼野鸡杂志
※ “Live”、“新闻”、“转录”此类文章每日发文数总上限为3篇，
自删与板主删除，同样计入额度 ※